NCT03318978View on ClinicalTrials.gov

Benzo[a]Pyrene Ultralow Dose-Response Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

January 1, 2024

Study Completion Date

February 1, 2024

Conditions
Environmental Exposure
Interventions
DRUG

[14C]-benzo[a]pyrene

Oral micro-dose range (25, 50, 100 and 250 ng)

Trial Locations (1)

97331

Clinical Research Facility, 407 Linus Pauling Science Center, Oregon State University, Corvallis

All Listed Sponsors
collaborator

National Institute of Environmental Health Sciences (NIEHS)

NIH

collaborator

Lawrence Livermore National Laboratory

OTHER

collaborator

Pacific Northwest National Laboratory

FED

lead

Oregon State University

OTHER

NCT03318978 - Benzo[a]Pyrene Ultralow Dose-Response Study | Biotech Hunter | Biotech Hunter